A Study to Test the Safety and Tolerability of a New Medication in the Treatment of Schizophrenia

• Status: Completed
• Trial end date: 2005-10-01
• Target enrollment: 0
• Participant gender: All

Summary

A 1-year outpatient study to test the safety and tolerability of a new medication in the treatment of schizophrenia

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sunovion
• Treatments: Lurasidone Hydrochloride

Criteria

• Patients must have participated in study D1050196 (A Study to Test the Effectiveness and Safety of a New Medication in the Treatment of Schizophrenia) and either:

• Successfully completed

• OR

• Patients must have been discontinued after a minimum of 2 weeks of treatment due to lack of efficacy